Prostate Cancer Screening: Weighing the Benefits and Risks
Renewed calls for a national prostate cancer screening program in the UK, championed by figures like former Prime Minister Rishi Sunak, have sparked debate about the effectiveness and potential harms of widespread testing. Prostate cancer is now the most commonly diagnosed cancer in men in the UK 1, but the path to effective early detection remains complex.
The Case for Screening
Rishi Sunak has become an ambassador for Prostate Cancer Research, advocating for a targeted national screening program, particularly for high-risk men 1. He believes early detection could save countless lives 2 and potentially save the NHS money 3. Prostate Cancer Research’s campaign focuses on rolling out a targeted national screening program for men at high risk, alongside investments in better diagnostic tools and artificial intelligence for future universal screening 1.
The Challenges of Current Screening Methods
Despite the potential benefits, current screening methods face significant limitations. The standard blood test used for early detection, the prostate-specific antigen (PSA) test, is not accurate enough for general population screening. Its sensitivity is only around 20%, compared to 50-91% for breast and cervical cancer tests 4. Factors like benign prostate enlargement, infections, and even recent exercise can lead to false positives, triggering unnecessary tests and investigations 4. Conversely, false negatives can occur, falsely reassuring men who do have the disease.
The ERSPC Trial and Its Implications
The European Randomized Study of Screening for Prostate Cancer (ERSPC) trial, a large-scale study across eight European countries, revealed that the absolute risk reduction from prostate cancer screening was only 0.2%. This means approximately one in 500 men screened experienced a benefit – preventing one prostate cancer death 4. The study also found that screening was more likely to detect low-risk cancers (twice as likely) and less likely to detect high-risk cancers (44% less likely) 4.
The Need for Improved Diagnostic Tools
A key dilemma is the need for a test that can accurately identify aggressive prostate cancers, particularly in younger men. Current tests struggle to differentiate between leisurely-growing, non-lethal tumors and those that require immediate intervention. Recent diagnostic tools, such as the EpiSwitch PSE blood test developed by Oxford BioDynamics, show promise with 94% accuracy 1. This test is currently available privately in the UK through healthcare providers like Goodbody Clinic and The London Clinic 1.
Informed Decision-Making
Currently, men aged 50 or over considering a PSA test should discuss the pros and cons with their GP to make an informed choice. Until more accurate diagnostic tools become available, a universal national screening program remains challenging to justify.
Rishi Sunak highlighted a report by Prostate Cancer Research recommending targeted screening and the use of new, AI-enhanced diagnostic tests to aid early detection 3.